After Africa, Aspen Australasia is the second largest revenue contributor to Regional Brands, with a comprehensive portfolio of medicines comprising Regional and Global Brands, including prescription and OTC products, as well as Sterile Focus Brands. There is also a manufacturing site in Australia, which produces FDF and undertakes third-party manufacturing.
|Circadin||Hormonal hypnotic sedative|
|Eltroxin||Thyroid hormone replacement|
|Marcaine||Regional and spinal anaesthetic|
NUMBER OF PERMANENT EMPLOYEES
Number of products launched:
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
|Commercial Pharmaceuticals||5 107||4 680||9|
|Regional Brands||4 464||3 955||13|
|Sterile Focus Brands||643||725||(11)|
|Manufacturing – FDF||596||532||12|
|Total||5 703||5 212||9|
Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue is by place of manufacture.
- The Australia and New Zealand OTC market was valued at AUD4,5 billion in June 2022 and grew 12,9% driven by recovery of various therapeutic segments specifically the Cough/Cold/Flu and related segments as a result of stay-at-home COVID-19 treatments and severe cold and flu season.
- The total pharmaceutical segment excluding the grocery channel grew 9,2% June 2022.
Source: IQVIA June 2022